- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04293523
48-месячное исследование по оценке долгосрочной эффективности Elocta для здоровья суставов (A-MORE)
48-месячное многоцентровое обсервационное исследование для оценки долгосрочной эффективности Elocta на здоровье суставов
This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.
Обзор исследования
Подробное описание
Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.
Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.
The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
-
Berlin, Германия
- Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
-
Bonn, Германия
- Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
-
Frankfurt, Германия
- Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
-
Frankfurt, Германия
- Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
-
Hamburg, Германия
- Universitätsklinikum Hamburg-Eppendorf (UKE)
-
Hanover, Германия
- Medizinische Hochschule Hannover
-
Hanover, Германия
- Werlhof-Institut für Hämostaseologie GmbH
-
Heidelberg, Германия
- SRH-Klinikum Heidelberg
-
Mörfelden-Walldorf, Германия
- HZRM Hämöphilie Zentrum Rhein Main
-
München, Германия
- Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München
-
-
-
-
-
Thessaloniki, Греция
- Ippokrateio Hospital Thessaloniki (adult department)
-
Thessaloniki, Греция
- Ippokrateio Hospital Thessaloniki (pediatric department)
-
-
-
-
-
Barcelona, Испания
- Sant Johan De Deu
-
Barcelona, Испания
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, Испания
- Hospital Vall d'Hebron
-
Cruces, Испания
- Hospital Universitario Cruces
-
Donostia / San Sebastian, Испания
- Hospital Universitario Donostia
-
Murcia, Испания
- Hospital Virgen de la Arrixaca
-
Málaga, Испания
- Hospital Universitario Carlos Haya
-
Navarro, Испания
- Complejo Hospitalario de Navarra
-
Oviedo, Испания
- Hospital Universitario Central de Asturias (HUCA)
-
Palma de Mallorca, Испания
- Hospital Universitario Son Espases
-
Seville, Испания
- Hospital Universitario Virgen del Rocío
-
Vigo, Испания
- Hospital Alvaro Cunqueiro
-
-
-
-
-
Bari, Италия
- University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
-
Cesena, Италия
- AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
-
Genova, Италия
- Giannina Gaslini Institute
-
Milan, Италия
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Parma, Италия
- University Hospital of Parma, AOUP, Haemophilia Center
-
Rome, Италия
- Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
-
Torino, Италия
- Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
-
-
-
-
-
Groningen, Нидерланды
- University Medical Center Groningen/UMCG
-
-
-
-
-
Muscat, Оман
- The Royal Hospital
-
-
-
-
-
Riyadh, Саудовская Аравия
- Dr Suliman Al Habib Hospital Riyadh
-
Riyadh, Саудовская Аравия
- King Faisal Specialised Hospital, KFSH Riyadh, Children
-
Riyadh, Саудовская Аравия
- King Faisal Specialist Hospital KFSH, Adults
-
Riyadh, Саудовская Аравия
- Riyadh Military Hospital (P.S.M.C)
-
-
-
-
-
Ljubljana, Словения
- University Medical Centre Ljubljana Division of Paediatrics
-
-
-
-
-
Canterbury, Соединенное Королевство
- East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
-
London, Соединенное Королевство
- Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
-
-
-
-
-
Helsinki, Финляндия
- Helsinki University Central Hospital, New Children Hospital
-
Turku, Финляндия
- Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
-
-
-
-
-
Brno, Чехия
- University Hospital Brno
-
Ostrava, Чехия
- University Hospital Ostrava
-
Prague, Чехия
- Dept. of Pediatric Haematology and Oncology, University Hospital Motol
-
-
-
-
-
Bern, Швейцария
- Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
-
Lausanne, Швейцария
- Service et Laboratoire central d'hématologie, Adults
-
Sankt Gallen, Швейцария
- Zentrum für Labormedizin
-
Zurich, Швейцария
- Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
-
-
-
-
-
Gothenburg, Швеция
- Hematologimottagning Sahlgrenska
-
Malmö, Швеция
- Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
-
-
-
-
-
Tallinn, Эстония
- Lastehaigla, Tallinn (Tallinn Children´s Hospital)
-
Tallinn, Эстония
- The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Ребенок
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.
Описание
Inclusion Criteria:
- Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
- Have a diagnosis of haemophilia A
- At enrolment on prophylactic treatment with Elocta, independent of participation in the study
Exclusion Criteria:
- Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
- Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Hemophilia A patients
All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice. |
Extended half-life factor VIII product
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Joint health: Target joint development
Временное ограничение: 48 months
|
Number of target joints |
48 months
|
|
Joint health: Target joint resolution
Временное ограничение: 48 months
|
Number of resolved target joints |
48 months
|
|
Joint health: Target joint recurrence
Временное ограничение: 48 months
|
Number of recurring target joints |
48 months
|
|
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
Временное ограничение: 48 months
|
Number of joint bleeding events per year, for treated bleeds |
48 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
Временное ограничение: 48 months
|
The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome. |
48 months
|
|
Global Gait Score, and/or joint score items for elbows, knees and ankles.
Временное ограничение: 48 months
|
The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles. The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome. |
48 months
|
|
Joint and physical evaluation for elbows, knees and ankles.
Временное ограничение: 48 months
|
The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome. |
48 months
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
Временное ограничение: 48 months
|
Number of bleeding events per year, for treated bleeds |
48 months
|
|
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
Временное ограничение: 48 months
|
Number of bleeding events per year, for all bleeds |
48 months
|
|
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
Временное ограничение: 48 months
|
Percentage (%) of study population with zero (0) joint bleeds |
48 months
|
|
Effectiveness of Elocta: Work productivity and impairment
Временное ограничение: 48 months
|
Assessed by WPAI-SHP questionnaire |
48 months
|
|
Effectiveness of Elocta: Quality of Life
Временное ограничение: 48 months
|
Assessed by Haemo-QoL/Haem-A-QoL questionnaire |
48 months
|
|
Effectiveness of Elocta: Physical activity level
Временное ограничение: 48 months
|
Assessed by the Saltin-Grimby scale |
48 months
|
|
Effectiveness of Elocta: Quality of Life
Временное ограничение: 48 months
|
Assessed by EQ-5D-5L/EQ-5D-Y questionnaire |
48 months
|
|
Effectiveness of Elocta: Severity of joint health
Временное ограничение: 48 months
|
Assessed by Patient Global Impression of Severity of Joint Health questionnaire |
48 months
|
|
Effectiveness of Elocta: FVIII plasma levels
Временное ограничение: 48 months
|
Percentage (%) of FVIII plasma level |
48 months
|
|
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Временное ограничение: 48 months
|
Assessed by medication dose |
48 months
|
|
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Временное ограничение: 48 months
|
Assessed by total number of exposure days per medication |
48 months
|
|
Usage of Elocta: Annualised injection frequency per subject
Временное ограничение: 48 months
|
Assessed by prescription |
48 months
|
|
Usage of Elocta: Annualised factor consumption per subject
Временное ограничение: 48 months
|
Assessed by prescription [IU/kg] |
48 months
|
|
Usage of Elocta: Adherence
Временное ограничение: 48 months
|
Investigator assessed (Percentage (%)) |
48 months
|
|
Exploratory Objective
Временное ограничение: 48 months
|
Influence of different Elocta prophylaxis regimens on long term joint health |
48 months
|
|
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
Временное ограничение: 48 months
|
Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level |
48 months
|
|
Exploratory Objective: Explore adherence to prescribed treatment regimen
Временное ограничение: 48 months
|
florio HAEMO captured treatment adherence scores |
48 months
|
|
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
Временное ограничение: 48 months
|
florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps) |
48 months
|
|
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
Временное ограничение: 48 months
|
florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels |
48 months
|
|
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
Временное ограничение: 48 months
|
florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Временное ограничение: 48 months
|
Target joint development, resolution and recurrence |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Временное ограничение: 48 months
|
Annualised joint bleeding rate (AJBR) for treated bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Временное ограничение: 48 months
|
Ultrasound (HEAD-US) |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Временное ограничение: 48 months
|
Clinical joint scoring (HJHS) |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Временное ограничение: 48 months
|
Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Временное ограничение: 48 months
|
Occurrence of zero (0) joint bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Временное ограничение: 48 months
|
Quality of Life assessed by Haemo-QoL/Haem-A-QoL |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Временное ограничение: 48 months
|
Physical activity level assessed by the Saltin-Grimby scale |
48 months
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Study Physician, Swedish Orphan Biovitrum
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Генетические заболевания, врожденные
- Гематологические заболевания
- Нарушения свертывания крови
- Геморрагические расстройства
- Нарушения свертывания крови, наследственные
- Нарушения белковой коагуляции
- Врожденные, наследственные и неонатальные заболевания и аномалии
- Гемики и лимфатические заболевания
- Гемофилия А
- рекомбинантный фактор свертывания VIII слитый с Fc фрагментом иммуноглобулина G
Другие идентификационные номера исследования
- Sobi.Elocta-005
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .